| 000 | 01612 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518041429.0 | ||
| 264 | 0 | _c20200623 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a2213-7173 | ||
| 024 | 7 |
_a10.1016/j.jgar.2019.05.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHanafy, Amr Shaaban | |
| 245 | 0 | 0 |
_aRefractory Helicobacter pylori gastritis: The hidden predictors of resistance. _h[electronic resource] |
| 260 |
_bJournal of global antimicrobial resistance _c12 2019 |
||
| 300 |
_a194-200 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacology |
| 650 | 0 | 4 |
_aClarithromycin _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Bacterial |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aDyspepsia _xmicrobiology |
| 650 | 0 | 4 | _aEndoscopy, Gastrointestinal |
| 650 | 0 | 4 |
_aFeces _xmicrobiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHelicobacter Infections _xdiagnosis |
| 650 | 0 | 4 |
_aHelicobacter pylori _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevofloxacin _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPoint Mutation |
| 650 | 0 | 4 | _aPolymorphism, Restriction Fragment Length |
| 650 | 0 | 4 |
_aRNA, Ribosomal, 23S _xgenetics |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSalvage Therapy |
| 700 | 1 | _aSeleem, Waseem M | |
| 773 | 0 |
_tJournal of global antimicrobial resistance _gvol. 19 _gp. 194-200 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jgar.2019.05.015 _zAvailable from publisher's website |
| 999 |
_c29713870 _d29713870 |
||